Timing of Folic Acid Administration in Vitamin B12 Deficiency

Critical Safety Principle

Initiating folic acid before confirming that vitamin B12 deficiency has been excluded or adequately treated can mask the anemia of B12 deficiency and precipitate irreversible neurological damage. 1

Hydroxocobalamin (1 mg intramuscular) should be started immediately upon diagnosis of vitamin B12 deficiency. 2
Folic acid supplementation may be introduced only after vitamin B12 replacement has been established and the patient is receiving adequate cobalamin therapy. 1
In cases of documented folate deficiency (with B12 deficiency excluded), oral folic acid 5 mg daily should be given for at least 4 months. 1

Neurological involvement: 1 mg intramuscular hydroxocobalamin on alternate days until no further neurological improvement is observed. 2
No neurological involvement: 1 mg intramuscular hydroxocobalamin three times per week for 2 weeks. 2

Do not rely solely on serum vitamin B12 levels; employ active B12 (holotranscobalamin) or functional biomarkers such as methylmalonic acid or homocysteine for accurate diagnosis. 2
In malabsorption conditions (e.g., pernicious anemia, post‑bariatric surgery, significant gastrointestinal disease), oral vitamin B12 therapy should be avoided; intramuscular hydroxocobalamin remains the standard of care. 2
Avoid cyanocobalamin in patients with renal impairment (eGFR < 50 mL/min/1.73 m²) because its cyanide moiety can accumulate as thiocyanate; prefer hydroxocobalamin or methylcobalamin. 2

Do not delay initiation of intramuscular hydroxocobalamin while awaiting specialist consultation when neurological symptoms are present; start treatment promptly and arrange urgent neurology/hematology referral concurrently. 2

In young women of child‑bearing age, routine folic acid supplementation for neural‑tube defect prevention does not appear to cause substantial harm from masking vitamin B12 deficiency, given the low prevalence (< 1 %) of severe B12 depletion in this group. 4
Multivitamin preparations that contain both folic acid and vitamin B12 reduce the risk of masking; however, therapeutic‑dose folic acid should still be administered separately and only after confirming adequate B12 status. 4